vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Legacy Education Inc. (LGCY). Click either name above to swap in a different company.
Legacy Education Inc. is the larger business by last-quarter revenue ($19.2M vs $10.7M, roughly 1.8× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs 10.6%, a 12.8% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 40.7%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Legacy Education Inc. is a professional educational service provider focused on financial literacy, real estate investment, entrepreneurship, and personal wealth management training programs. It mainly serves individual learners across North America, Europe and select Asia-Pacific markets, offering both in-person workshops and online digital courses to help users build practical financial and business skills.
ABUS vs LGCY — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $19.2M |
| Net Profit | $2.5M | $2.0M |
| Gross Margin | — | — |
| Operating Margin | 13.9% | 13.3% |
| Net Margin | 23.5% | 10.6% |
| Revenue YoY | 522.2% | 40.7% |
| Net Profit YoY | 112.7% | 46.0% |
| EPS (diluted) | $0.01 | $0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $19.2M | ||
| Q3 25 | — | $19.4M | ||
| Q2 25 | $10.7M | $18.0M | ||
| Q1 25 | — | $18.6M | ||
| Q4 24 | — | $13.6M | ||
| Q3 24 | — | $14.0M | ||
| Q4 23 | $2.1M | — | ||
| Q3 23 | $4.7M | — |
| Q4 25 | — | $2.0M | ||
| Q3 25 | — | $2.2M | ||
| Q2 25 | $2.5M | $1.2M | ||
| Q1 25 | — | $2.8M | ||
| Q4 24 | — | $1.4M | ||
| Q3 24 | — | $2.1M | ||
| Q4 23 | — | — | ||
| Q3 23 | $-20.1M | — |
| Q4 25 | — | 13.3% | ||
| Q3 25 | — | 13.9% | ||
| Q2 25 | 13.9% | 11.1% | ||
| Q1 25 | — | 19.7% | ||
| Q4 24 | — | 12.2% | ||
| Q3 24 | — | 19.1% | ||
| Q4 23 | -967.2% | — | ||
| Q3 23 | -462.8% | — |
| Q4 25 | — | 10.6% | ||
| Q3 25 | — | 11.3% | ||
| Q2 25 | 23.5% | 6.8% | ||
| Q1 25 | — | 15.2% | ||
| Q4 24 | — | 10.3% | ||
| Q3 24 | — | 14.9% | ||
| Q4 23 | — | — | ||
| Q3 23 | -431.6% | — |
| Q4 25 | — | $0.15 | ||
| Q3 25 | — | $0.16 | ||
| Q2 25 | $0.01 | $0.07 | ||
| Q1 25 | — | $0.21 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | — | $0.21 | ||
| Q4 23 | $-0.12 | — | ||
| Q3 23 | $-0.12 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $21.1M |
| Total DebtLower is stronger | $0 | $660.3K |
| Stockholders' EquityBook value | $83.0M | $46.1M |
| Total Assets | $103.3M | $73.1M |
| Debt / EquityLower = less leverage | 0.00× | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $21.1M | ||
| Q3 25 | — | $20.6M | ||
| Q2 25 | $37.4M | $20.3M | ||
| Q1 25 | — | $17.3M | ||
| Q4 24 | — | $16.9M | ||
| Q3 24 | — | $21.5M | ||
| Q4 23 | $126.0M | — | ||
| Q3 23 | $17.5M | — |
| Q4 25 | — | $660.3K | ||
| Q3 25 | — | $776.9K | ||
| Q2 25 | $0 | $1.4M | ||
| Q1 25 | — | $1.0M | ||
| Q4 24 | — | $1.1M | ||
| Q3 24 | — | $758.2K | ||
| Q4 23 | $0 | — | ||
| Q3 23 | $0 | — |
| Q4 25 | — | $46.1M | ||
| Q3 25 | — | $43.7M | ||
| Q2 25 | $83.0M | $41.0M | ||
| Q1 25 | — | $39.3M | ||
| Q4 24 | — | $36.4M | ||
| Q3 24 | — | $32.6M | ||
| Q4 23 | $106.0M | — | ||
| Q3 23 | $119.3M | — |
| Q4 25 | — | $73.1M | ||
| Q3 25 | — | $72.1M | ||
| Q2 25 | $103.3M | $69.2M | ||
| Q1 25 | — | $67.1M | ||
| Q4 24 | — | $62.1M | ||
| Q3 24 | — | $50.6M | ||
| Q4 23 | $144.4M | — | ||
| Q3 23 | $158.6M | — |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.02× | ||
| Q2 25 | 0.00× | 0.03× | ||
| Q1 25 | — | 0.03× | ||
| Q4 24 | — | 0.03× | ||
| Q3 24 | — | 0.02× | ||
| Q4 23 | 0.00× | — | ||
| Q3 23 | 0.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $1.1M |
| Free Cash FlowOCF − Capex | — | $512.7K |
| FCF MarginFCF / Revenue | — | 2.7% |
| Capex IntensityCapex / Revenue | 0.0% | 2.8% |
| Cash ConversionOCF / Net Profit | -6.24× | 0.52× |
| TTM Free Cash FlowTrailing 4 quarters | — | $4.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.1M | ||
| Q3 25 | — | $1.1M | ||
| Q2 25 | $-15.7M | $3.0M | ||
| Q1 25 | — | $918.7K | ||
| Q4 24 | — | $659.0K | ||
| Q3 24 | — | $3.2M | ||
| Q4 23 | $-17.3M | — | ||
| Q3 23 | $-21.8M | — |
| Q4 25 | — | $512.7K | ||
| Q3 25 | — | $809.7K | ||
| Q2 25 | — | $2.9M | ||
| Q1 25 | — | $596.6K | ||
| Q4 24 | — | $466.8K | ||
| Q3 24 | — | $2.9M | ||
| Q4 23 | — | — | ||
| Q3 23 | $-21.8M | — |
| Q4 25 | — | 2.7% | ||
| Q3 25 | — | 4.2% | ||
| Q2 25 | — | 16.2% | ||
| Q1 25 | — | 3.2% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 21.1% | ||
| Q4 23 | — | — | ||
| Q3 23 | -468.4% | — |
| Q4 25 | — | 2.8% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | 0.0% | 0.5% | ||
| Q1 25 | — | 1.7% | ||
| Q4 24 | — | 1.4% | ||
| Q3 24 | — | 1.7% | ||
| Q4 23 | 0.0% | — | ||
| Q3 23 | 0.7% | — |
| Q4 25 | — | 0.52× | ||
| Q3 25 | — | 0.48× | ||
| Q2 25 | -6.24× | 2.45× | ||
| Q1 25 | — | 0.33× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 1.52× | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
